/s3/static.nrc.nl/wp-content/uploads/2025/11/06165823/061125VER_2022378981_1-1.jpg)
Obesity Medication Use Rises Alongside Reported Poisonings, Expert Says Access Should Be Limited
Amsterdam, Netherlands – Reports of adverse effects linked to obesity medications have doubled in the past year, according to the National Poisons Details center (NVIC). The center recorded 105 cases of poisoning in 2025, compared to 50 in 2024, coinciding with a surge in medication usage from 80,000 to 170,000 individuals. When factoring in those using lower doses of semaglutide – commonly known as Ozempic – for diabetes treatment, the total number of users reaches 270,000.
While the increase in reported incidents isn’t entirely unexpected given the growing user base, experts caution that the term “poisoning” can be misleading. Many reported cases involve common side effects like vomiting and gastrointestinal distress, often stemming from rapid dosage increases or excessively high doses. A meaningful contributing factor is the increasing trend of individuals self-medicating by purchasing these medications online without proper medical supervision.
“Not everyone gets obesity medication – and that is right,” states a leading professor, speaking on the matter. The expert emphasizes the importance of controlled access to these powerful drugs, highlighting that they are not a worldwide solution and require careful medical oversight. The rise in self-treatment underscores the need for greater awareness of potential risks and the importance of consulting with healthcare professionals before starting any new medication regimen. The professor’s comments come as healthcare systems grapple with balancing increased demand for these medications with ensuring patient safety and responsible prescribing practices.
